Fingolimod Hydrochloride
-
Subject Areas on Research
- Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.
- Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.
- FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes.
- Modulation of adaptive immune responses by sphingosine-1-phosphate.
- Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer's disease.
- S1P-Dependent trafficking of intracellular yersinia pestis through lymph nodes establishes Buboes and systemic infection.
- Should we B-leavin' now?
- Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma.
- Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
- The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
- The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.
- The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.